Viridian Therapeutics, Inc.
VRDN· Nasdaq
VRDNViridian Therapeutics, Inc.
Filed Mar 9, 2023 · 10-K · 68 days after period end · 0001590750-23-000002
derived · Computed from the longer spans the company filed.
| Metric | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures | Q4 2019 |
|---|---|---|---|---|
| Revenue | $105.00K | $214.00K | $54.00K | $880.00K |
| Net Income | -$45.79M | -$28.95M | -$90.74M | -$10.12M |
| EPS Diluted | — | — |
Viridian Therapeutics, Inc. · CIK 1590750 · Engraved from SEC EDGAR
| — |
| -$0.31 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2022 · filed Mar 9, 2023 · 68 d after period end
